Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 3,800 shares, an increase of 171.4% from the March 31st total of 1,400 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 25,600 shares, the days-to-cover ratio is currently 0.1 days.
Analysts Set New Price Targets
Separately, Craig Hallum initiated coverage on Acasti Pharma in a report on Wednesday, February 7th. They issued a “buy” rating and a $6.00 price objective on the stock.
Get Our Latest Stock Analysis on ACST
Acasti Pharma Stock Up 1.0 %
Acasti Pharma (NASDAQ:ACST – Get Free Report) last posted its earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. As a group, research analysts predict that Acasti Pharma will post -1.44 earnings per share for the current fiscal year.
About Acasti Pharma
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Articles
- Five stocks we like better than Acasti Pharma
- What Are Dividends? Buy the Best Dividend Stocks
- Hasbro’s Management Made All the Right Calls This Quarter
- What is a Secondary Public Offering? What Investors Need to Know
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- The How and Why of Investing in Gold Stocks
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.